Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis

Proteomics - Clinical Applications

Volumn 7, Issue 7-8, 2013, Pages 541-549

  Seeley, Erin H ^a   Washington, Mary K ^a   Caprioli, Richard M ^a,b   M'Koma, Amosy E ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Colon tissue profiling; Crohn's colitis; Mass spectrometry; Ulcerative colitis

Indexed keywords

ACCURACY; ADULT; ARTICLE; CLASSIFICATION; COLON CROHN DISEASE; COLON MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SUBMUCOSA; SUPPORT VECTOR MACHINE; ULCERATIVE COLITIS;

COLON TISSUE PROFILING; CROHN'S COLITIS; MASS SPECTROMETRY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROTEOMICS; YOUNG ADULT;

EID: 84881527142     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200107     Document Type: Article

References (41)

1. Blumberg, R., Cho, J., Lewis, J., Wu, G., Inflammatory bowel disease: an update on the fundamental biology and clinical management. Gastroenterology 2011, 140, 1701-1703.
2. M'Koma, A. E., Moses, H. L., Adunyah, S. E., Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy does not necessarily eliminate pouch related cancer incidences. Int. J. Colorect. Dis. 2011, 26, 533-552.
3. Ullman, T. A., Itzkowitz, S. H., Intestinal inflammation and cancer. Gastroenterology 2011, 140, 1807-1816.
4. Kader, H. A., Tchernev, V. T., Satyaraj, E., Lejnine, S. et al., Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 2005, 100, 414-423.
5. Burczynski, M. E., Peterson, R. L., Twine, N. C., Zuberek, K. A. et al., Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 2006, 8, 51-61.
6. Langhorst, J., Elsenbruch, S., Koelzer, J., Rueffer, A. et al., Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008, 103, 162-169.
7. Anand, V., Russell, A. S., Tsuyuki, R., Fedorak, R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can. J. Gastroenterol. 2008, 22, 33-36.
8. Shinzaki, S., Iijima, H., Nakagawa, T., Egawa, S. et al., IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am. J. Gastroenterol. 2008, 103, 1173-1181.
9. Sandborn, W. J., Loftus, E. V., Jr., Colombel, J. F., Fleming, K. A. et al., Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 2001, 7, 192-201.
10. Fukushima, K., Yonezawa, H., Fiocchi, C., Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm. Bowel Dis. 2003, 9, 290-301.
11. Shkoda, A., Werner, T., Daniel, H., Gunckel, M. et al., Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J. Proteome. Res. 2007, 6, 1114-1125.
12. Walkiewicz, D., Werlin, S. L., Fish, D., Scanlon, M. et al., Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14, 669-673.
13. Sidler, M. A., Leach, S. T., Day, A. S., Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm. Bowel Dis. 2008, 14, 359-366.
14. Felley-Bosco, E., Andre, M., Proteomics and chronic inflammatory bowel diseases. Pathol. Res. Pract. 2004, 200, 129-133.
15. Bossuyt, X., Serologic markers in inflammatory bowel disease. Clin. Chem. 2006, 52, 171-181.
16. Costa, F., Mumolo, M. G., Ceccarelli, L., Bellini, M. et al., Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54, 364-368.
17. Froslie, K. F., Jahnsen, J., Moum, B. A., Vatn, M. H., Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133, 412-422.
18. Baert, F., Moortgat, L., Van Assche, G., Caenepeel, P. et al., Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138, 463-468.
19. Romberg-Camps, M. J., Dagnelie, P. C., Kester, A. D., Hesselink-van de ruijs, M. A. et al., Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am. J. Gastroenterol. 2009, 104, 371-383.
20. Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. et al., Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139, 1147-1155.
21. Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K. et al., Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119, 15-22.
22. Gisbert, J. P., Bermejo, F., Perez-Calle, J. L., Taxonera, C. et al., Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis. 2009, 15, 1190-1198.
23. Travis, S. P., Farrant, J. M., Ricketts, C., Nolan, D. J. et al., Predicting outcome in severe ulcerative colitis. Gut 1996, 38, 905-910.
24. Turner, D., Leach, S. T., Mack, D., Uusoue, K. et al., Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010, 59, 1207-1212.
25. Haines, M. L., Ajlouni, Y., Irving, P. M., Sparrow, M. P. et al., Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 1301-1307.
26. Waljee, A. K., Joyce, J. C., Wang, S., Saxena, A. et al., Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin. Gastroenterol. Hepatol. 2010, 8, 143-150.
27. Maser, E. A., Villela, R., Silverberg, M. S., Greenberg, G. R., Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4, 1248-1254.
28. Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J. et al., Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010, 362, 1383-1395.
29. Keighley, M. R., The final diagnosis in pouch patients for presumed ulcerative colitis may change to Crohn's disease: patients should be warned of the consequences. Acta Chir. Iugosl. 2000, 47, 27-31.
30. Shen, B., Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm. Bowel Dis. 2009, 15, 284-294.
31. Shen, B., Remzi, F. H., Brzezinski, A., Lopez, R. et al., Risk factors for pouch failure in patients with different phenotypes of Crohn's disease of the pouch. Inflamm. Bowel Dis. 2008, 14, 942-948.
32. Wagner-Bartak, N. A., Levine, M. S., Rubesin, S. E., Laufer, I. et al., Crohn's disease in the ileal pouch after total colectomy for ulcerative colitis: findings on pouch enemas in six patients. AJR Am. J. Roentgenol. 2005, 184, 1843-1847.
33. M'Koma, A. E., Seeley, E. H., Washington, M. K., Schwartz, D. A. et al., Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm. Bowel Dis. 2011, 17, 875-883.
34. M'Koma, A. E., Seeley, E. H., Wise, P. E., Washington, M. K. et al., Proteomic analysis of colonic submucosa differentiates Crohn's and ulcerative colitis. Annual Congress - Digestive Disease Week, Chicago, IL 2009, p. 600.
35. M'Koma, A. E., Seeley, E. H., Wise, P. E., Washington, M. K. et al., Proteomic Patterns of Colonic Submucosa Discriminates Inflammatory Colitides. Annual Congress - The American Society of Colon and Rectal Surgeons, Hollywood, FL 2009, p. 166.
36. Puri, K. S., Suresh, K. R., Gogtay, N. J., Thatte, U. M., Declaration of Helsinki, 2008: implications for stakeholders in research. J. Postgrad. Med. 2009, 55, 131-134.
37. Cook, M. G., Dixon, M. F., An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut 1973, 14, 255-262.
38. Chaurand, P., Schwartz, S. A., Billheimer, D., Xu, B. J. et al., Integrating histology and imaging mass spectrometry. Anal. Chem. 2004, 76, 1145-1155.
39. Chaurand, P., DaGue, B. B., Pearsall, R. S., Threadgill, D. W. et al., Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 2001, 1, 1320-1326.
40. Cornett, D. S., Mobley, J. A., Dias, E. C., Andersson, M. et al., A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol. Cell Proteomics 2006, 5, 1975-1983.
41. Um, J. W., M'Koma, A. E., Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Tech. Coloproctol. 2011, 15, 7-16.